Ironwood Pharmaceuticals | IRWD - Sales Revenues

Stock Price
4.50
Daily Change
0.05 1.12%
Monthly
10.29%
Yearly
164.71%
Q1 Forecast
4.74

Ironwood Pharmaceuticals reported $122.06M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Almirall EUR 560.46M 71.95M Jun/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amarin USD 49.67M 23.07M Sep/2025
Ardelyx USD 110.33M 12.67M Sep/2025
Astellas Pharma JPY 571.21B 46.89B Dec/2025
AstraZeneca USD 15.19B 733M Sep/2025
Charles River Laboratories USD 1000M 32.14M Sep/2025
Exact Sciences USD 851M 39.9M Sep/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ironwood Pharmaceuticals USD 122.06M 36.82M Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Moderna USD 1.02B 878M Sep/2025
Myriad Genetics USD 205.7M 7.4M Sep/2025
Pacira USD 179.52M 1.58M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Takeda JPY 1.19T 80B Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025